Access Program Information
An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic
stem cell transplantation.
This Program is available for female and male who are recipients of allogenic HSCT and who
have been newly diagnosed with acute GvHD.
Alpha 1 antitrypsin is being tested in a Phase 2/3 Clinical Study to evaluate the safety and
efficacy of Glassia (1-4) as an add-on bio pharmacotherapy to conventional steroid treatment
in subjects with acute graft versus host disease with lower gastrointestinal involvement
(NCT02956122).